微球在肝细胞癌经导管肝动脉化疗栓塞术治疗中的应用及研究进展  

Clinical application and advances in research on microspheres in TACE for hepatocellular carcinoma

作　　者：邢冬娟[1] 徐爱民[1] 

机构地区：[1]东方肝胆外科医院放射介入三科,上海200438

出　　处：《中华肝胆外科杂志》2011年第12期1023-1026,共4页Chinese Journal of Hepatobiliary Surgery

基　　金：自然科学基金资助（30973458）

摘　　要：肝细胞癌（HCC）占原发性肝癌的90％以上。手术切除是治疗HCC的最佳治疗方案。但是，由于许多患者在诊断时已经处于晚期或存在多发病灶，所以只有少数患者能够施行手术。对于不能切除的肝细胞癌患者只有通过姑息性治疗来控制症状、提高生活质量、延长生存期。大量文献数据显示经导管肝动脉化疗栓塞术（transcatheter hepatic arterial chemoembolization，TACE）是非手术治疗的首选。传统的栓塞剂如碘油、明胶海绵等的应用虽然可延长患者的生存期，但由于这些栓塞剂存在易被清除、降解的局限性，从而影响栓塞效果。微球作为一种新型的栓塞剂，目前受到国内外研究者的广泛关注。根据微球的性质及作用将其分为两大类：单纯微球及载体微球。本研究就此两类微球做一综述。Hepatocellular carcinoma （HCC） accounts for more than 90% of primary liver cancer. Surgical resection is the standard modality of treatment. However, resection can only be performed in a minority of patients at the time of diagnosis. Data from several recently published studies are encouraging and suggest that TACE （transcatheter hepatic arterial chemoembolization） is superior to conserva- tive treatment in patients with hepatocellular carcinoma who are not eligible for surgery. The traditional embolic agents such as iodized oil and gelatin sponge significantly prolonged survival in patients with HCC. However, the effects of these embolic agents are temporary. A new embolic agent, microspheres has attracted a lot of attention in our country and abroad. These microspheres can be divided into two categories： pure mierospheres and carrier mierospheres. In this paper, we review these two types of microspheres.

关 键 词：微球 经导管肝动脉化疗栓塞术 肝细胞癌 

分 类 号：R735.7[医药卫生—肿瘤]